ATLANTA, GA – – (Globe Newswire – April 4, 2025) – – Holzer & Holzer, LLC is investigating whether Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX) complied with federal securities laws. On April 3, 2025, Aldeyra announced it received a Complete Response Letter (“CRL”) from the FDA regarding the Company’s resubmitted New Drug Application (“NDA”) for reproxalap. The FDA indicated that “the NDA failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes.” Following this news, the price of the Company’s stock dropped.

If you purchased Aldeyra stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/aldeyra-therapeutics/ to discuss your legal rights.